Biotech Values

[ghmm]

VRTX:

I realize the book was talking mainly about the development of a transplant drug on some HCV work (that Boger didn't want to get into). What the book spoke to me most about was their culture which in retrospect hearing company presentations seemed still present.

There are two major things that stick out.
1) I basically have the sense they think they are better then everyone (probably common and not necessarily bad in a modest degree but I sense a much higher level with VRTX).
2) Shareholders are seen only as a source for funds. Maybe that is why Emmens was bought in?

I agree with all you wrote on VRTX I am a bit skeptical on how big the CF drugs can be and I think if Management would swallow some pride they could probably get more life out of Incivek.